Company Encyclopedia
View More
name
JINGXIN
002020.SZ
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, cephalosporin, and biopharma products; and API products, including ciprofloxacin, ciprofloxacin hydrochloride, ciprofloxacin lactate, levofloxacin hemihydrate, levofloxacin hydrochloride, levofloxacin lactate, enrofloxacin, enrofloxacin hydrochloride, simvastatin, rosuvastatin calcium, pitavastatin calcium, ticagrelor, rivaroxaban, apixaban, cisapride, levetiracetam, brivaracetam, sertraline HCI, rivastigmine bitartrate, pramipexole dihydrochloride, memantine hydrochloride, empagliflozin, dapagliflozin, marbofloxacin, and moxifloxacin. It also provides intermediates; and medical display products, such as diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, ultrasonic medical displays, and other products.
3.157 T
002020.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking94/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.41%B
    • Profit Margin17.82%A
    • Gross Margin50.90%B
  • Growth ScoreD
    • Revenue YoY-6.63%D
    • Net Profit YoY-1.21%C
    • Total Assets YoY-7.04%D
    • Net Assets YoY-2.98%D
  • Cash ScoreC
    • Cash Flow Margin561.07%C
    • OCF YoY-6.63%D
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreB
    • Gearing Ratio28.74%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    JINGXIN: Cumulative repurchase of 609 million yuan

    JINGXIN announced that as of October 31, 2025, the company repurchased 47.2713 million shares through a dedicated securities account for share repurchase via centralized bidding, accounting for 5.49% of the company's current total share capital. The highest transaction price for the repurchased shares was RMB 14.41 per share, the lowest transaction price was RMB 11.86 per share, and the total transaction amount was RMB 609 million

    Zhitong·
    SZ
    002020
    -0.21%
    Zhitong·
    SZ
    002020
    -0.21%

    Hanshow Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025

    Hanshow Technology Co., Ltd. reported its earnings for the nine months ending September 30, 2025. The company experienced a decline in sales, reporting CNY 2,809.06 million, down from CNY 3,157.5 million the previous year. Net income also fell to CNY 314.39 million from CNY 528.47 million year-over-year. Basic and diluted earnings per share from continuing operations decreased to CNY 0.7624, compared to CNY 1.3901 a year ago.

    marketscreener·
    SZ
    301275
    +2.12%
    marketscreener·
    SZ
    301275
    +2.12%

    JINGXIN has repurchased 5.49% of its shares, costing 609 million yuan

    According to the Zhitong Finance APP, JINGXIN announced that the company repurchased 47,271,295 shares through centralized bidding as of August 31, 2025, accounting for 5.49% of the company's current total share capital, with a total transaction amount of 609 million yuan (excluding transaction fees)

    Zhitong·
    SZ
    002020
    -0.21%
    Zhitong·
    SZ
    002020
    -0.21%

    JINGXIN: Net profit in the first half of 2025 is 388 million yuan, a year-on-year decrease of 3.54%

    JINGXIN announced that in the first half of 2025, operating revenue was 2.017 billion yuan, a year-on-year decrease of 6.20%. Net profit was 388 million yuan, a year-on-year decrease of 3.54%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

    Zhitong·
    SZ
    002020
    -0.21%
    Zhitong·
    SZ
    002020
    -0.21%

    JINGXIN: As of the announcement date, a total of 290 million yuan of the raised funds for temporarily supplementing working capital has been fully returned to the special account for raised funds, and the usage period has not exceeded 12 months

    Zhitong·
    SZ
    002020
    -0.21%
    Zhitong·
    SZ
    002020
    -0.21%
    © 2025 Longbridge｜Disclaimer